80 related articles for article (PubMed ID: 21533343)
1. The quinolinone derivative vesnarinone potentiates the cytotoxicity of doxorubicin in HL-60 leukemia cells.
Yamamoto M; Maehara Y; Sakaguchi Y; Kusumoto T; Baba H; Sugimachi K
Int J Oncol; 1997 Jan; 10(1):53-7. PubMed ID: 21533343
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: studies on human gastric cancer tissue xenografts in nude mice.
Kawai K; Konishi Y; Izumi K; Sato M; Adachi M; Hozumi M
Anticancer Res; 1998; 18(1A):405-12. PubMed ID: 9568110
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone).
Isaka K; Fujito A; Sagawa Y; Yudate T; Nishi H; Ito H; Takayama M
Oncol Rep; 2002; 9(6):1299-305. PubMed ID: 12375038
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
Sato M; Harada K; Bando T; Shirakami T; Nakashiro K; Yoshida H; Nakai S; Kawai K; Adachi M
Cancer Lett; 1995 May; 91(1):1-9. PubMed ID: 7750082
[TBL] [Abstract][Full Text] [Related]
5. Differentiation inducing effects of vesnarinone on human glioma cells.
Tanaka S; Nishihara T; Nagashima T; Kawai K; Nakai S; Adachi M
J Clin Neurosci; 1997 Jan; 4(1):57-62. PubMed ID: 18638925
[TBL] [Abstract][Full Text] [Related]
6. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (vesnarinone) on the growth of gastric cancer cell lines.
Yokozaki H; Ito R; Ono S; Hayashi K; Tahara E
Cancer Lett; 1999 Jun; 140(1-2):121-8. PubMed ID: 10403550
[TBL] [Abstract][Full Text] [Related]
7. Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell lines.
Fujita M; Tsuchida T; Fujita T; Higashino K
Oncol Rep; 1999; 6(2):353-7. PubMed ID: 10023004
[TBL] [Abstract][Full Text] [Related]
8. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia.
Matsui S; Matsumori A; Sasayama S
Life Sci; 1994; 55(22):1735-41. PubMed ID: 7968253
[TBL] [Abstract][Full Text] [Related]
9. Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia.
Nara N; Kurokawa H; Tohda S; Tomiyama J; Nagata K; Tanikawa S
Exp Hematol; 1997 Mar; 25(3):199-204. PubMed ID: 9091294
[TBL] [Abstract][Full Text] [Related]
10. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
Fujiwara H; Arima N; Otsubo H; Matsushita K; Hidaka S; Arimura K; Kukita T; Yamaguchi K; Tanaka H
Exp Hematol; 1997 Oct; 25(11):1180-6. PubMed ID: 9328455
[TBL] [Abstract][Full Text] [Related]
11. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.
Sato S; Tomoyasu S; Okabe-Kado J; Hozumi M; Tsuruoka N; Nakai S; Adachi M; Honma Y
Exp Hematol; 1996 Jan; 24(1):37-42. PubMed ID: 8536790
[TBL] [Abstract][Full Text] [Related]
12. Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis.
Manna SK; Aggarwal BB
J Immunol; 2000 Jun; 164(11):5815-25. PubMed ID: 10820260
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.
Kubo K; Matsuzaki Y; Kato A; Terai S; Okita K
Int J Oncol; 1999 Jan; 14(1):41-6. PubMed ID: 9863007
[TBL] [Abstract][Full Text] [Related]
14. [Solid phase clean-up and determination of vesnarinone in plasma by high performance liquid chromatography].
Wu S; Wu C
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Mar; 23(1):106-9. PubMed ID: 1398618
[TBL] [Abstract][Full Text] [Related]
15. Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro.
Nabeshima R; Aizawa S; Nakano M; Toyama K; Sugimoto K; Kaidow A; Imai T; Handa H
Exp Hematol; 1997 Jun; 25(6):509-15. PubMed ID: 9197329
[TBL] [Abstract][Full Text] [Related]
16. Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells.
Asakura T; Ohkawa K; Takahashi N; Takada K; Inoue T; Yokoyama S
Br J Cancer; 1997; 76(10):1333-7. PubMed ID: 9374380
[TBL] [Abstract][Full Text] [Related]
17. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Matsui S; Matsumori A; Matoba Y; Uchida A; Sasayama S
J Clin Invest; 1994 Sep; 94(3):1212-7. PubMed ID: 8083362
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
20. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Bertolet BD
Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
